目的：探讨应用伊马替尼治疗高危胃肠道间质瘤（GIST）的临床疗效。方法：回顾性分析2010年1月—2015年6月收治的56例接受伊马替尼靶向治疗的高危GIST患者临床资料，并对疗效进行分析。结果：19例无手术切除机会的患者经伊马替尼（400 mg/d）治疗6~8个月后，无完全缓解（CR）者，部分缓解（PR）14例，疾病稳定（SD）4例，疾病进展（PD）1例；7例（36.8%）PR患者获得手术切除机会。35例行手术切除后服用伊马替尼（400 mg/d）1年，随访3例复发，1年复发率8.6%；2例终断服药，无法评估疗效。结论：伊马替尼治疗GIST疗效肯定，对于高危GIST患者，术前新辅助化疗能让无法手术切除的肿瘤获得手术机会，术后辅助化疗可能提高无瘤生存率，不良反应较轻能够耐受。
Clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor
Objective: To explore the clinical effect of imatinib targeted therapy on high risk gastrointestinal stromal tumor (GISTS). Methods: The clinical data of 56 patients with high risk GIST undergoing imatinib targeted therapy from January 2010 to June 2015 were reviewed, and the therapeutic efficacy was analyzed. Results: Nineteen patients, who had no chance of surgical resection, received imatinib (400 mg/d) therapy for 6 to 8 months, and of them, none achieved complete response (CR), 14 cases obtained partial response (PR), 4 cases had stable disease (SD), and one case presented progressive disease (PD); 7 PR cases (36.8%) obtained a chance for tumor resection. Thirty-five patients received imtinib (400 mg/d) treatment for one year after surgical resection, and of them, recurrence occurred in 3 cases (8.6%) during follow-up and the one-year recurrence rate was 8.6%; 2 cases did not continue to take the medication and their results could not be determined. Conclusion: Imatinib has significant efficacy in GIST patients, and in those with high risk GIST, its preoperative neoadjuvant chemotherapy may offer a chance of surgical resection for the unresectable tumors, and its postoperative adjuvant chemotherapy may improve the tumor-free survival with tolerable adverse effects.